Biology:GPR56

From HandWiki
Revision as of 22:09, 15 February 2024 by Rjetedi (talk | contribs) (simplify)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Protein-coding gene in the species Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

G protein-coupled receptor 56 also known as TM7XN1 is a protein encoded by the ADGRG1 gene.[1] GPR56 is a member of the adhesion GPCR family.[2][3] Adhesion GPCRs are characterized by an extended extracellular region often possessing N-terminal protein modules that is linked to a TM7 region via a domain known as the GPCR-Autoproteolysis INducing (GAIN) domain.[4]

GPR56 is expressed in liver, muscle, tendon, neural, and cytotoxic lymphoid cells in human as well as in hematopoietic precursor, muscle, and developing neural cells in the mouse.[5] GPR56 has been shown to have numerous role in cell guidance/adhesion as exemplified by its roles in tumour inhibition and neuron development.[6][7] More recently it has been shown to be a marker for cytotoxic T cells and a subgroup of Natural killer cells.[8]

Ligands

GPR56 binds transglutaminase 2 to suppress tumor metastasis[9] and binds collagen III to regulate cortical development and lamination.[10]

Signaling

GPR56 couples to q/11 protein upon association with the tetraspanins CD9 and CD81.[11] Forced GPR56 expression activates NF-kB, PAI-1, and TCF transcriptional response elements.[12] The splicing of GPR56 induces tumorigenic responses as a result of activating the transcription of genes, such as COX2, iNOS, and VEGF85. GPR56 couples to the Gα12/13 protein and activates RhoA and mammalian target of rapamycin (mTOR) pathway upon ligand binding.[10][13][14][15] Lack of the N-terminal fragment (NTF) of GPR56 causes stronger RhoA signaling and β-arrestin accumulation, leading to extensive ubiquitination of the C-terminal fragment (CTF).[16] Finally, GPR56 suppresses PKCα activation to regulate angiogenesis.[17]

Function

Studies in the hematopoietic system disclosed that during endothelial to hematopoietic stem cell transition, Gpr56 is a transcriptional target of the heptad complex of hematopoietic transcription factors, and is required for hematopoietic cluster formation.[18] Recently, two studies showed that GPR56, is a cell autonomous regulator of oligodendrocyte development through Gα12/13 proteins and Rho activation.[14][19] Della Chiesa et al. demonstrate that GPR56 is expressed on CD56dull natural killer (NK) cells.[20] Lin and Hamann's group show all human cytotoxic lymphocytes, including CD56dull NK cells and CD27CD45RA+ effector-type CD8+ T cells, express GPR56.[8]

Clinical significance

GPR56 was the first adhesion GPCR causally linked to a disease. Loss-of-function mutations in GPR56 cause a severe cortical malformation known as bilateral frontoparietal polymicrogyria (BFPP).[21][22][23][24][25][26][27] Investigating the pathological mechanism of disease-associated GPR56 mutations in BFPP has provided mechanistic insights into the functioning of adhesion GPCRs. Researchers demonstrated that disease-associated GPR56 mutations cause BFPP via multiple mechanisms.[28][29][30][31] Li et al. demonstrated that GPR56 regulates pial basement membrane (BM) organization during cortical development. Disruption of the Gpr56 gene in mice leads to neuronal malformation in the cerebral cortex, which resulted in 4 critical pathological morphologies: defective pial BM, abnormal localized radial glial endfeet, malpositioned Cajal-Retzius cells, and overmigrated neurons.[32] Furthermore, the interaction of GPR56 and collagen III inhibits neural migration to regulate lamination of the cerebral cortex.[10] Next to GPR56, the α3β1 integrin is also involved in pial BM maintenance. Study from Itga3 (α3 integrin)/Gpr56 double knockout mice showed increased neuronal overmigration compared to Gpr56 single knockout mice, indicating cooperation of GPR56 and α3β1 integrin in modulation of the development of the cerebral cortex.[33] More recently, the Walsh laboratory showed that alternative splicing of GPR56 regulates regional cerebral cortical patterning.[34]

In depression patients, blood GPR56 mRNA expression increases only in responders and not non-responders to serotonin-norepinephrine reuptake inhibitor treatment.[35] Furthermore, GPR56 was down-regulated in the prefrontal cortex of individuals with depression that died by suicide.

Outside the nervous system, GPR56 has been linked to muscle function and male fertility. The expression of GPR56 is upregulated during early differentiation of human myoblasts. Investigation of Gpr56 knockout mice and BFPP patients showed that GPR56 is required for in vitro myoblast fusion via signaling of serum response factor (SRF) and nuclear factor of activated T-cell (NFAT), but is not essential for muscle development in vivo.[36] Additionally, GPR56 is a transcriptional target of peroxisome proliferator-activated receptor gamma coactivator 1-alpha 4 and regulates overload-induced muscle hypertrophy through Gα12/13 and mTOR signaling.[15] Therefore, the study of knockout mice revealed that GPR56 is involved in testis development and male fertility.[37] In melanocytic cells GPR56 gene expression may be regulated by MITF.[38]

Mutations in GPR56 cause the brain developmental disorder BFPP, characterized by disordered cortical lamination in frontal cortex.[21] Mice lacking expression of GPR56 develop a comparable phenotype.[32] Furthermore, loss of GPR56 leads to reduced fertility in male mice, resulting from a defect in seminiferous tubule development.[37] GPR56 is expressed in glioblastoma/astrocytoma[12] as well as in esophageal squamous cell,[39] breast, colon, non-small cell lung, ovarian, and pancreatic carcinoma.[40] GPR56 was shown to localize together with α-actinin at the leading edge of membrane filopodia in glioblastoma cells, suggesting a role in cell adhesion/migration.[12] In addition, recombinant GPR56-NTF protein interacts with glioma cells to inhibit cellular adhesion. Inactivation of Von Hippel-Lindau (VHL) tumor-suppressor gene and hypoxia suppressed GPR56 in a renal cell carcinoma cell line, but hypoxia influenced GPR56 expression in breast or bladder cancer cell lines.[41] GPR56 is a target gene for vezatin, an adherens junctions transmembrane protein, which is a tumor suppressor in gastric cancer.[42] Xu et al. used an in vivo metastatic model of human melanoma to show that GPR56 is downregulated in highly metastatic cells.[9] Later, by ectopic expression and RNA interference they confirmed that GPR56 inhibits melanoma tumor growth and metastasis. Silenced expression of GPR56 in HeLa cells enhanced apoptosis and anoikis, but suppressed anchorage-independent growth and cell adhesion.[40] High ecotropic viral integration site-1 acute myeloid leukemia (EVI1-high AML) expresses GPR56 that was found to be a transcriptional target of EVI1.[43] Silencing expression of GPR56 decreases adhesion, cell growth and induces apoptosis through reduced RhoA signaling. GPR56 suppresses the angiogenesis and melanoma growth through inhibition of vascular endothelial growth factor (VEGF) via PKCα signaling pathway.[17] Furthermore, GPR56 expression was found to be negatively correlated with the malignancy of melanomas in human patients.

References

  1. "International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors". Pharmacological Reviews 67 (2): 338–67. April 2015. doi:10.1124/pr.114.009647. PMID 25713288. 
  2. Stacey M, Yona S (2011). Adhesion-GPCRs: Structure to Function (Advances in Experimental Medicine and Biology). Berlin: Springer. ISBN 978-1-4419-7912-4. 
  3. "Sticky signaling--adhesion class G protein-coupled receptors take the stage". Science Signaling 6 (276): re3. May 2013. doi:10.1126/scisignal.2003825. PMID 23695165. 
  4. "A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis". The EMBO Journal 31 (6): 1364–78. March 2012. doi:10.1038/emboj.2012.26. PMID 22333914. 
  5. "International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors". Pharmacological Reviews 67 (2): 338–67. Apr 2015. doi:10.1124/pr.114.009647. PMID 25713288. 
  6. "GPR56 Interacts with Extracellular Matrix and Regulates Cancer Progression". Adhesion-GPCRS. Advances in Experimental Medicine and Biology. 706. 2010. pp. 98–108. doi:10.1007/978-1-4419-7913-1_8. ISBN 978-1-4419-7912-4. 
  7. "Adhesion-GPCRS in the CNS". Adhesion-GPCRS. Advances in Experimental Medicine and Biology. 706. 2010. pp. 87–97. doi:10.1007/978-1-4419-7913-1_7. ISBN 978-1-4419-7912-4. 
  8. 8.0 8.1 "Specific expression of GPR56 by human cytotoxic lymphocytes". Journal of Leukocyte Biology 90 (4): 735–40. October 2011. doi:10.1189/jlb.0211092. PMID 21724806. 
  9. 9.0 9.1 "GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis". Proceedings of the National Academy of Sciences of the United States of America 103 (24): 9023–8. June 2006. doi:10.1073/pnas.0602681103. PMID 16757564. Bibcode2006PNAS..103.9023X. 
  10. 10.0 10.1 10.2 "G protein-coupled receptor 56 and collagen III, a receptor-ligand pair, regulates cortical development and lamination". Proceedings of the National Academy of Sciences of the United States of America 108 (31): 12925–30. August 2011. doi:10.1073/pnas.1104821108. PMID 21768377. Bibcode2011PNAS..10812925L. 
  11. "Dynamic regulation of a GPCR-tetraspanin-G protein complex on intact cells: central role of CD81 in facilitating GPR56-Galpha q/11 association". Molecular Biology of the Cell 15 (5): 2375–87. May 2004. doi:10.1091/mbc.E03-12-0886. PMID 15004227. 
  12. 12.0 12.1 12.2 "GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion". Oncogene 24 (10): 1673–82. March 2005. doi:10.1038/sj.onc.1208395. PMID 15674329. 
  13. "Orphan G protein-coupled receptor GPR56 regulates neural progenitor cell migration via a G alpha 12/13 and Rho pathway". The Journal of Biological Chemistry 283 (21): 14469–78. May 2008. doi:10.1074/jbc.M708919200. PMID 18378689. 
  14. 14.0 14.1 "The adhesion GPCR Gpr56 regulates oligodendrocyte development via interactions with Gα12/13 and RhoA". Nature Communications 6: 6122. January 2015. doi:10.1038/ncomms7122. PMID 25607772. Bibcode2015NatCo...6.6122A. 
  15. 15.0 15.1 "G protein-coupled receptor 56 regulates mechanical overload-induced muscle hypertrophy". Proceedings of the National Academy of Sciences of the United States of America 111 (44): 15756–61. November 2014. doi:10.1073/pnas.1417898111. PMID 25336758. Bibcode2014PNAS..11115756W. 
  16. "The N terminus of the adhesion G protein-coupled receptor GPR56 controls receptor signaling activity". The Journal of Biological Chemistry 286 (33): 28914–21. August 2011. doi:10.1074/jbc.M111.247973. PMID 21708946. 
  17. 17.0 17.1 "GPR56 Regulates VEGF production and angiogenesis during melanoma progression". Cancer Research 71 (16): 5558–68. August 2011. doi:10.1158/0008-5472.CAN-10-4543. PMID 21724588. 
  18. "Whole-transcriptome analysis of endothelial to hematopoietic stem cell transition reveals a requirement for Gpr56 in HSC generation". The Journal of Experimental Medicine 212 (1): 93–106. January 2015. doi:10.1084/jem.20140767. PMID 25547674. 
  19. "The adhesion G protein-coupled receptor GPR56 is a cell-autonomous regulator of oligodendrocyte development". Nature Communications 6: 6121. January 2015. doi:10.1038/ncomms7121. PMID 25607655. Bibcode2015NatCo...6.6121G. 
  20. "GPR56 as a novel marker identifying the CD56dull CD16+ NK cell subset both in blood stream and in inflamed peripheral tissues". International Immunology 22 (2): 91–100. February 2010. doi:10.1093/intimm/dxp116. PMID 20008459. 
  21. 21.0 21.1 "G protein-coupled receptor-dependent development of human frontal cortex". Science 303 (5666): 2033–6. March 2004. doi:10.1126/science.1092780. PMID 15044805. Bibcode2004Sci...303.2033P. 
  22. "Genotype-phenotype analysis of human frontoparietal polymicrogyria syndromes". Annals of Neurology 58 (5): 680–7. November 2005. doi:10.1002/ana.20616. PMID 16240336. 
  23. "Bilateral frontoparietal polymicrogyria, Lennox-Gastaut syndrome, and GPR56 gene mutations". Epilepsia 50 (6): 1344–53. June 2009. doi:10.1111/j.1528-1167.2008.01787.x. PMID 19016831. 
  24. "GPR56-related bilateral frontoparietal polymicrogyria: further evidence for an overlap with the cobblestone complex". Brain 133 (11): 3194–209. November 2010. doi:10.1093/brain/awq259. PMID 20929962. 
  25. "A novel GPR56 mutation causes bilateral frontoparietal polymicrogyria". Pediatric Neurology 45 (1): 49–53. July 2011. doi:10.1016/j.pediatrneurol.2011.02.004. PMID 21723461. 
  26. "Conventional magnetic resonance imaging and diffusion tensor imaging studies in children with novel GPR56 mutations: further delineation of a cobblestone-like phenotype". Neurogenetics 14 (1): 77–83. February 2013. doi:10.1007/s10048-012-0352-7. PMID 23274687. 
  27. "Bilateral frontoparietal polymicrogyria: a novel GPR56 mutation and an unusual phenotype". Neuropediatrics 46 (2): 134–8. April 2015. doi:10.1055/s-0034-1399754. PMID 25642806. 
  28. "Disease-associated mutations affect GPR56 protein trafficking and cell surface expression". Human Molecular Genetics 16 (16): 1972–85. August 2007. doi:10.1093/hmg/ddm144. PMID 17576745. 
  29. "Biochemical characterization of genetic mutations of GPR56 in patients with bilateral frontoparietal polymicrogyria (BFPP)". Biochemical and Biophysical Research Communications 366 (2): 314–20. February 2008. doi:10.1016/j.bbrc.2007.11.071. PMID 18042463. 
  30. "Disease-associated GPR56 mutations cause bilateral frontoparietal polymicrogyria via multiple mechanisms". The Journal of Biological Chemistry 286 (16): 14215–25. April 2011. doi:10.1074/jbc.M110.183830. PMID 21349848. 
  31. "Disease-associated mutations prevent GPR56-collagen III interaction". PLOS ONE 7 (1): e29818. 2012. doi:10.1371/journal.pone.0029818. PMID 22238662. Bibcode2012PLoSO...729818L. 
  32. 32.0 32.1 "GPR56 regulates pial basement membrane integrity and cortical lamination". The Journal of Neuroscience 28 (22): 5817–26. May 2008. doi:10.1523/JNEUROSCI.0853-08.2008. PMID 18509043. 
  33. "GPR56 functions together with α3β1 integrin in regulating cerebral cortical development". PLOS ONE 8 (7): e68781. 2013. doi:10.1371/journal.pone.0068781. PMID 23874761. Bibcode2013PLoSO...868781J. 
  34. "Evolutionarily dynamic alternative splicing of GPR56 regulates regional cerebral cortical patterning". Science 343 (6172): 764–8. February 2014. doi:10.1126/science.1244392. PMID 24531968. Bibcode2014Sci...343..764B. 
  35. "GPR56/ADGRG1 is associated with response to antidepressant treatment". Nature Communications 11 (1): 1635. April 2020. doi:10.1038/s41467-020-15423-5. PMID 32242018. Bibcode2020NatCo..11.1635B. 
  36. "G-protein coupled receptor 56 promotes myoblast fusion through serum response factor- and nuclear factor of activated T-cell-mediated signalling but is not essential for muscle development in vivo". The FEBS Journal 280 (23): 6097–113. December 2013. doi:10.1111/febs.12529. PMID 24102982. 
  37. 37.0 37.1 "GPR56 is essential for testis development and male fertility in mice". Developmental Dynamics 239 (12): 3358–67. December 2010. doi:10.1002/dvdy.22468. PMID 20981830. 
  38. "Novel MITF targets identified using a two-step DNA microarray strategy". Pigment Cell & Melanoma Research 21 (6): 665–76. December 2008. doi:10.1111/j.1755-148X.2008.00505.x. PMID 19067971. 
  39. "Differential expression of G-protein coupled receptor 56 in human esophageal squamous cell carcinoma". Cancer Letters 233 (2): 265–70. February 2006. doi:10.1016/j.canlet.2005.03.018. PMID 15916848. 
  40. 40.0 40.1 "Orphan G protein-coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway". Molecular Cancer Therapeutics 6 (6): 1840–50. June 2007. doi:10.1158/1535-7163.MCT-07-0066. PMID 17575113. 
  41. "Identification of novel VHL target genes and relationship to hypoxic response pathways". Oncogene 24 (28): 4549–58. June 2005. doi:10.1038/sj.onc.1208649. PMID 15824735. 
  42. "VEZT, a novel putative tumor suppressor, suppresses the growth and tumorigenicity of gastric cancer". PLOS ONE 8 (9): e74409. 2013. doi:10.1371/journal.pone.0074409. PMID 24069310. Bibcode2013PLoSO...874409M. 
  43. "Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56". Leukemia 27 (8): 1637–49. August 2013. doi:10.1038/leu.2013.75. PMID 23478665. 

External links